The regulatory landscape in tuberculosis integrated research platforms
European Respiratory Journal · 2026-11 · 68 (5) · 2600646
DOI: 10.1183/13993003.00646-2026 ↗Abstract
Background Tuberculosis (TB) is the infectious disease with the highest mortality burden globally. Despite a recently enriched drug pipeline, there has been limited progress in improving its treatment. Integrated research platforms (IRPs) provide a novel research framework which, by hosting adaptive platform trials, can streamline the evaluation of several new TB regimens, while reducing costs. However, there is no clear, evidence-based guidance on the use of IRPs for regulatory drug development in TB. Methods This consensus statement summarises the discussions and recommendations produced during the European Union Patient-Centric Clinical Trial Platforms (EU-PEARL) project. A multidisciplinary Task Force reviewed the literature regarding regulatory pathways for IRPs with special focus on TB and identified current gaps and needs, which were discussed by an extended panel in two consultations. Here we summarise the output of this process and propose possible ways to advance in the implementation of such platforms. Results and conclusion IRP coordinators are advised to seek early contact with national regulators and supranational bodies, including regulatory collaboration initiatives. To ensure regulatory acceptance, IRPs must prioritise careful design, including clear decision rules for phase transitions, and the development of surrogate makers. Furthermore, data leverage and stratification across groups could enhance IRP success. These efforts will not only strengthen the scientific validity of the IRP but also enhance its regulatory acceptability and impact on global TB treatment strategies.
EUVIMED